Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said a patent application was published for a patent, titled "Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer," which covers a method of treating cancer that comprises administering a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition in combination with a therapeutically effective amount of a systemic immunomodulatory cancer drug

13/282,145, "Method of Treating Hypertriglyceridemia," regarding Vascepa (icosapent ethyl...8,263,582, "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids," for the use of beclomethasone dipropionate in oral form

8,242,131 related to methods of treating middle-of-the-night insomnia with Intermezzo (low-dose zolpidem

It describes a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa

8,143,311, titled "Methods of Treating Fragile X Syndrome and Autism

The patents describe a method of treating pain by adhering a small-volume solid tablet containing sufentanil to the oral mucosa, as well as compositions and dosage forms broadly covering NanoTab formulations

8,071,551, titled "Methods and Compositions For Treating Diabetes," which covers methods for treating diabetes by administering alpha-1 antitrypsin (AAT) or a derivative of AAT

It covers methods of treating cancer using cytokine-antibody complexes produced by the firm's Dock-and-Lock technology

8,012,710, titled "Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders

Lorus Therapeutics Inc., of Toronto, was granted a patent covering methods of treating acute myeloid leukemia patients with LOR-2040 in combination with cytarabine

7,928,115, which covers methods of treating travelers' diarrhea with rifaximin

7,829,093 and 7,829,094 relating to methods of treating Type I diabetes and certain cancers using XOMA 052 or other IL-1 beta antibodies with similar binding characteristics to XOMA 052

7,811,560, titled "Compositions And Methods For Treating Collagen-Mediated Diseases

The new claims encompass methods of treating herpes simplex I infections, including herpes labialis

7,514,405, titled "Methods for treating transplant rejection," which covers the treatment of chronic transplant rejection by administering drug candidate VT-111 in combination with an immunosuppressant

7,645,448, titled "Class of Therapeutics Protein-Based Molecules," which covers its sialidase pharmaceutical compositions, including lead compound DAS181 (Fludase) and methods of treating or preventing viral infection by influenza and parainfluenza

That claim also covers methods of treating CEA-expressing cancers

Claims include a method for treating patients diagnosed with opiate addiction using a small implantable rod-shaped polymeric matrix comprising buprenorphine blended with ethylene vinyl acetate copolymer

7,611,704, which covers compositions and methods of treating virus infections using bavituximab and similar phosphatidylserine-targeting antibodies, either alone or an immunoconjugates attached to antiviral agents, as well as in combination with other antiviral agents